Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 4, 2000, Pages 335-344

  Flowers, James L ^a   Ludeman, Susan M ^a,b   Gamcsik, Michael P ^a   Colvin, O Michael ^a   Shao, Kai Liu ^b   Boal, Jila H ^b   Springer, James B ^a   Adams, David J ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b CATHOLIC UNIVERSITY OF AMERICA   (United States)

Author keywords

4 Hydroperoxycyclophosphamide; Chloroethylaziridine; Cyclophosphamide; In vitro assay; Phenylketophosphamide

Indexed keywords

AZIRIDINE DERIVATIVE; CHLOROETHYLAZIRIDINE; CYCLOPHOSPHAMIDE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CELL VIABILITY; CHEMOSENSITIVITY; CRYSTALLIZATION; CYTOTOXICITY; IN VITRO STUDY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; TUMOR CELL CULTURE; VOLATILIZATION;

EID: 0034019459     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050049     Document Type: Article

References (28)

1. 1. Alarcon RA, Meienhofer J (1971) Formation of the cytotoxic aldehyde acrolein during in vitro degradation of cyclophosphamide. Nat New Biol 233: 250
2. 2. Blomgren H, Hallstrom M (1989) Release of a volatile factor from solutions of oxazaphosphorines which damage normal and malignant cells. Methods Find Exp Clin Pharmacol 11(6): 391
3. 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: comparisons with phosphoramide mustard. J Med Chem 32: 1768
4. 31P NMR evidence for equilibration of cis-and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution. J Med Chem 27: 490
5. 5. Bosanquet AG, Burlton AR (1994) Airborne cytotoxicity in the DiSC assay caused by solutions of treosulfan but not busulfan. Cytotechnology 16: 131
6. 6. Boyd VL, Summers MF, Ludeman SM, Egan W, Zon G, Regan JB (1987) NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. 2. Direct observation, characterization, and reactivity studies of iminocyclophosphamide and related species. J Med Chem 30: 366
7. 7. Chang L, Gusewitch GA, Chiritton DB, Folz JC, Lebeck LK, Nehlsen-Cannarella SL (1993) Rapid flow cytometric assay for the assessment of natural killer cell activity. J Immunol Methods 166(1): 45
8. 8. Colvin M, Chabner BA (1991) Alkylating agents. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practice. J.L. Lippincott, Philadelphia, pp 276-313
9. 9. DeClerck LS, Bridts CH, Mertens AM, Moens MM, Stevens WJ (1994) Use of fluorescent dyes in the determination of adherence of human leucocytes to endothelial cells and the effect of fluorochromes on cellular function. J Immunol Methods 172: 115
10. 10. Fenselau C, Lehman JP, Myles A, Brandt J, Yost GS, Friedman OM, Colvin OM (1982) Iminocyclophosphamide as a chemically reactive metabolite of cyclophosphamide. Drug Metab Dispos 10: 636
11. 11. Frei E III, Teicher BA, Holden SA, Cathcart KNS, Wang Y (1988) Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 48: 6417
12. 6-alkylguanine-DNA alkyltransferase. Cancer Chemother Pharmacol 43(1): 80
13. 13. Friedman OM, Myles A, Colvin M (1979) Cyclophosphamide and related phosphoramide mustards. Current status and future prospects. Adv Cancer Chemother 1: 143
14. 14. Grafstrom RC (1990) In vitro studies of aldehyde effects related to human respiratory carcinogenesis. Mutat Res 238: 175
15. 15. Hales BF, Ludeman SM, Boyd VL (1989) Embryotoxicity of phenyl ketone analogues of cyclophosphamide. Teratology 39: 31
16. 16. Horton ND, Mamiya BM, Kehrer JP (1997) Relationships between cell density, glutathione, and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Toxicology 122: 111
17. 17. Lichtenfels R, Biddison W, Schulz H, Vogt AB, Martin R (1994) CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods 172: 227
18. 18. Lu H, Chan KK (1996) Gas chromatographic-mass spectrometric assay for N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in rat plasma. J Chromatogr B Biomed Appl 678: 219
19. 19. Ludeman SM, Boyd VL, Regan JB, Gallo KA, Zon G, Ishii K (1986) Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of 'phenylketophosphamide' and similar compounds related to the cyclophosphamide metabolite aldophosphamide. J Med Chem2 9: 716
20. 20. Popadopoulos NG, Dedoussis GVZ, Spanakos G, Gritzapis AD, Baxevanis CN, Papamichail M (1994) An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods 177: 101
21. 21. Rauen HM, Norpoth K (1968) A volatile alkylating agent in the exhaled air following the administration of Endoxan. Klin Wochenschr 46: 272
22. 15N labeled isophosphoramide mustard. J Labeled Compound Radiopharm 34: 231
23. 23. Shulman-Roskes EM, Noe DA, Gamcsik MP, Marlow AL, Hilton J, Hausheer FH, Colvin OM, Ludeman SM (1998) The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and P-N bond hydrolysis reactions. J Med Chem 41: 515
24. 24. Stec WJ (1982) Cyclophosphamide and its congeners. Organophosphorus Chem 13: 145
25. 25. Takamizawa A, Matsumoto S, Iwata T, Tochino Y, Katagiri K, Yamaguchi K, Shiratori O (1975) Studies on cyclophosphamide metabolites and their related compounds. 2. Preparation of an active species of Cyclophosphamide and related compounds. J Med Chem 18: 376
26. 26. Wang XM, Terasaki PI, Rankin J, George W, Chia D, Zhong HP, Hardy S (1993) A new microcellular cytotoxicity test based on calcein-AM release. Hum Immunol 37: 264
27. 27. Wrabetz E, Peter G, Hohorst HJ (1980) Does Acrolein Contribute To The Toxicity Of Cyclophosphamide? J Cancer Res Clin Oncol 98: 119
28. 28. Zon G, Ludeman SM, Brandt JA, Boyd VL, Özkan G, Egan W, Shao KL (1984) NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis-and trans-4-hydroxycyclophosphamide with aldophosphamide, and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways. J Med Chem 27: 466